Table 3 A multivariate model in which each miRNA was analyzed individually together with differentiation grade as a predictor for PFS in wild-type- KRAS and mutated- KRAS patients treated with chemotherapy, bevacizumab and cetuximab
Overall n = 32 | KRAS wild-type n = 18 | KRAS mutation n = 14 | p-value | ||
|---|---|---|---|---|---|
MiR-27b | HR (95% CI) | 0.74 (0.38-1.42) | 0.94 (0.36-2.42) | 0.51 (0.20-1.32) | 0.38 |
p-value | 0.36 | 0.89 | 0.16 | ||
MiR-105 | HR (95% CI) | 1.04 (0.84-1.29) | 0.95 (0.76-1.21) | 1.22 (0.83-1.78) | 0.26 |
p-value | 0.72 | 0.69 | 0.32 | ||
MiR-155 | HR (95% CI) | 0.92 (0.62-1.35) | 0.77 (0.38-1.53) | 0.96 (0.60-1.51) | 0.60 |
p-value | 0.66 | 0.45 | 0.85 | ||
MiR-346 | HR (95% CI) | 0.83 (0.63-1.10) | 0.85 (0.61-1.19) | 0.72 (0.40-1.32) | 0.63 |
p-value | 0.20 | 0.34 | 0.29 | ||
MiR-181a | HR (95% CI) | 0.75 (0.46-1.22) | 0.70 (0.37-1.33) | 0.94 (0.44-2.02) | 0.57 |
p-value | 0.24 | 0.27 | 0.87 | ||
MiR-19a | HR (95% CI) | 0.96 (0.78-1.19) | 1.03 (0.80-1.33) | 0.74 (0.45-1.20) | 0.23 |
p-value | 0.73 | 0.82 | 0.22 | ||
MiR-200b | HR (95% CI) | 1.03 (0.72-1.47) | 0.90 (0.51-1.57) | 1.78 (0.87-3.62) | 0.18 |
p-value | 0.86 | 0.70 | 0.10 | ||
MiR-27a | HR (95% CI) | 0.74 (0.43-1.27) | 0.69 (0.31-1.54) | 0.71 (0.35-1.43) | 0.96 |
p-value | 0.27 | 0.37 | 0.34 | ||
MiR-30a | HR (95% CI) | 0.70 (0.44-1.10) | 0.77 (0.40-1.55) | 0.70 (0.37-1.34) | 0.86 |
p-value | 0.12 | 0.46 | 0.28 | ||
Let-7a | HR (95% CI) | 0.94 (0.59-1.50) | 0.89 (0.50-1.59) | 1.28 (0.46-3.58) | 0.55 |
p-value | 0.80 | 0.68 | 0.63 | ||
MiR-21 | HR (95% CI) | 0.89 (0.57-1.39) | 1.15 (0.52-2.55) | 0.81 (0.49-1.33) | 0.47 |
p-value | 0.61 | 0.74 | 0.40 | ||
MiR-96 | HR (95% CI) | 0.84 (0.59-1.20) | 0.74 (0.45-1.22) | 0.93 (0.55-1.58) | 0.54 |
p-value | 0.33 | 0.24 | 0.79 | ||
MiR-143 | HR (95% CI) | 0.73 (0.51-1.05) | 0.92 (0.56-1.51) | 0.63 (0.40-0.99) | 0.26 |
p-value | 0.09 | 0.74 | 0.04 | ||
MiR-217 | HR (95% CI) | 1.01 (0.87-1.16) | 0.85 (0.61-1.19) | 0.78 (0.56-1.08) | 0.72 |
p-value | 0.95 | 0.34 | 0.13 | ||
MiR-133a | HR (95% CI) | 0.81 (0.63-1.05) | 0.98 (0.68-1.43) | 0.66 (0.41-1.06) | 0.21 |
p-value | 0.12 | 0.92 | 0.09 | ||
MiR-133b | HR (95% CI) | 0.89 (0.70-1.13) | 1.04 (0.73-1.49) | 0.80 (0.55-1.17) | 0.32 |
p-value | 0.32 | 0.83 | 0.25 | ||
MiR-19b | HR (95% CI) | 0.95 (0.75-1.20) | 1.02 (0.77-1.34) | 0.66 (0.36-1.23) | 0.21 |
p-value | 0.65 | 0.91 | 0.19 |